BioLife Solutions Past Earnings Performance
Past criteria checks 0/6
BioLife Solutions's earnings have been declining at an average annual rate of -45.2%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 40.5% per year.
Key information
-45.2%
Earnings growth rate
-23.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 40.5% |
| Return on equity | -19.7% |
| Net Margin | -46.4% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How BioLife Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 143 | -66 | 80 | 19 |
| 30 Sep 23 | 155 | -102 | 81 | 19 |
| 30 Jun 23 | 162 | -83 | 79 | 17 |
| 31 Mar 23 | 163 | -146 | 74 | 15 |
| 31 Dec 22 | 162 | -140 | 69 | 15 |
| 30 Sep 22 | 155 | -106 | 67 | 14 |
| 30 Jun 22 | 148 | -96 | 64 | 14 |
| 31 Mar 22 | 139 | -15 | 57 | 14 |
| 31 Dec 21 | 119 | -9 | 48 | 12 |
| 30 Sep 21 | 97 | 5 | 38 | 10 |
| 30 Jun 21 | 74 | 4 | 29 | 9 |
| 31 Mar 21 | 53 | -20 | 23 | 7 |
| 31 Dec 20 | 48 | 2 | 22 | 7 |
| 30 Sep 20 | 42 | 7 | 18 | 6 |
| 30 Jun 20 | 37 | 16 | 17 | 5 |
| 31 Mar 20 | 34 | 39 | 15 | 4 |
| 31 Dec 19 | 27 | -2 | 14 | 3 |
| 30 Sep 19 | 25 | -32 | 12 | 2 |
| 30 Jun 19 | 23 | -39 | 11 | 2 |
| 31 Mar 19 | 22 | -44 | 10 | 1 |
| 31 Dec 18 | 20 | -25 | 9 | 1 |
| 30 Sep 18 | 17 | 1 | 8 | 1 |
| 30 Jun 18 | 15 | 0 | 7 | 1 |
| 31 Mar 18 | 12 | -2 | 7 | 1 |
| 31 Dec 17 | 11 | -3 | 7 | 1 |
| 30 Sep 17 | 10 | -5 | 6 | 1 |
| 30 Jun 17 | 9 | -6 | 7 | 2 |
| 31 Mar 17 | 9 | -7 | 7 | 2 |
| 31 Dec 16 | 8 | -7 | 8 | 2 |
| 30 Sep 16 | 8 | -5 | 8 | 2 |
| 30 Jun 16 | 7 | -5 | 8 | 2 |
| 31 Mar 16 | 7 | -4 | 8 | 2 |
| 31 Dec 15 | 6 | -4 | 7 | 1 |
| 30 Sep 15 | 6 | -4 | 7 | 1 |
| 30 Jun 15 | 6 | -4 | 6 | 1 |
| 31 Mar 15 | 6 | -4 | 6 | 1 |
| 31 Dec 14 | 6 | -3 | 5 | 1 |
| 30 Sep 14 | 7 | -3 | 5 | 1 |
| 30 Jun 14 | 8 | -2 | 4 | 1 |
| 31 Mar 14 | 9 | -2 | 4 | 1 |
| 31 Dec 13 | 9 | -1 | 4 | 0 |
| 30 Sep 13 | 9 | -1 | 3 | 0 |
| 30 Jun 13 | 8 | -1 | 3 | 0 |
Quality Earnings: BJX1 is currently unprofitable.
Growing Profit Margin: BJX1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BJX1 is unprofitable, and losses have increased over the past 5 years at a rate of 45.2% per year.
Accelerating Growth: Unable to compare BJX1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BJX1 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: BJX1 has a negative Return on Equity (-19.67%), as it is currently unprofitable.